Travere Therapeutics, Inc. (TVTX)
About Travere Therapeutics, Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $490.7M
- Net income
- -$25.5M
- Total assets
- $605.2M
- Market cap
- $4.3B
- Gross margin
- 97.9%
- Operating margin
- -12.8%
- Net margin
- -5.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $490.7M
- Cost of revenue
- $10.3M
- Gross profit
- $480.4M
- Operating expenses
- $543.2M
- Operating income
- -$62.8M
- Income tax
- $988.0K
- Net income
- -$25.5M
- EPS (basic)
- $-0.29
- EPS (diluted)
- $-0.29
Balance sheet
- Total assets
- $605.2M
- Current assets
- $437.6M
- Total liabilities
- $490.4M
- Current liabilities
- $159.9M
- Shareholders’ equity
- $114.8M
Cash flow
- Operating cash flow
- $37.8M
- Investing cash flow
- $27.9M
- Financing cash flow
- -$33.5M
- Net cash flow
- $34.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $4.3B
- EPS (diluted)
- $-0.29
- Shares outstanding
- 74.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 23, 2003
Travere Therapeutics, Inc. (TVTX) Stock Price
- Reported a net loss of $25.5M in FY2025.
- Revenue grew 147% from FY2020 to FY2025.
- Gross margin of 97.9%, net margin -5.2%.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Travere Therapeutics, Inc..
Write a review
News about Travere Therapeutics, Inc.
News & sentiment via Polygon.io
Travere Therapeutics, Inc.: frequently asked questions
Is Travere Therapeutics, Inc. an American company?
Travere Therapeutics, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Travere Therapeutics, Inc. headquartered?
Travere Therapeutics, Inc. is headquartered in San Diego, California, United States.
Is Travere Therapeutics, Inc. publicly traded?
Yes — Travere Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol TVTX on the NASDAQ.
What does Travere Therapeutics, Inc. do?
Travere Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
